A novel synthesized 3’, 5’-diprenylated chalcone mediates the proliferation of human leukemia cells by regulating apoptosis and autophagy pathways

Zhang, Yongqiang; Wen, Zhonghang; Wan, Ke; Yuan, Dongbo; Zeng, Xiaoping; Guang-yi, Liang; Zhu, Jianguo; Xu, Bixue; Luo, Heng

doi:10.1016/j.biopha.2018.06.153

Cited by 28 publications

(27 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We applied the same statistical analysis methods as previously reported [21]. A student's test was used for data analysis.…”

Section: Discussionmentioning

confidence: 99%

“…All equipment and biological agents used in this study were as previously reported [18,21]. The other reagents were of analytical grade.…”

Section: Methodsmentioning

confidence: 99%

“…Cell apoptosis level was determined by flow cytometry and Hoechst 33258 assay, as described previously [18,21]. Briefly, 5 × 10 6 PC3 cells were seeded in a 6-well plate and incubated for 12 h. The cells were treated with different concentrations of C10 (0, 2, 4, and 8 µmol/L) for 24 h, harvested, and stained with annexin-V-FITC and PI, followed by flow cytometric analysis.…”

Section: Cell Apoptosis Assaymentioning

confidence: 99%

“…Gene expression was detected at a transcriptional (RT-qPCR and semi-quantitative RT-qPCR) and protein level (Western blotting), as described previously [21]. GAPDH served as an endogenous control.…”

Section: Genes Expression Assaymentioning

confidence: 99%

“…We previously designed and synthesized a series of novel 3 ,5 -diprenylated chalcones aiming to identify those having an anti-proliferative effect. We identified three compounds showing inhibitory activity on tumor cell proliferation in vitro by inducing cell apoptosis and cell cycle arrest, and (E)-1-(2-hydroxy-4-methoxy-3,5-diprenyl) phenyl-3-(3-pyridinyl)propene-1-one (C10) exhibited potent anti-cancer activity with better selectivity and lower toxicity than the other two in leukemia cells [18,21]. Our research group conducted a systematic study on anticancer drugs targeting Fli-1.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3’, 5’-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

The friend leukemia integration 1 (Fli-1) gene is involved in the expression control of key genes in multiple pathogenic/physiological processes, including cell growth, differentiation, and apoptosis; this implies that Fli-1 is a strong candidate for drug development. In our previous study, a 3′,5′-diprenylated chalcone, (E)-1-(2-hydroxy-4-methoxy-3,5-diprenyl) phenyl-3-(3-pyridinyl)-propene-1-one (C10), was identified as a novel anti-prostate cancer (PCa) agent. Here, we investigated the molecular mechanisms underlying the anti-cancer effects of C10 on the growth, metastasis, and invasion of PC3 cells in vitro. Our results show that C10 exhibited a strong inhibitory effect on proliferation and metastasis of PC3 cells via several cellular and flow cytometric analyses. Further mechanism studies revealed that C10 likely serves as an Fli-1 agonist for regulating the expression of Fli-1 target genes including phosphatidylinositol 3-kinase (P110), murine double minute2 (MDM2), B-cell lymphoma-2 (Bcl-2), Src homology-2 domain-containing inositol 5-phosphatase 1 (SHIP-1), and globin transcription factor-1 (Gata-1) as well as the phosphorylation of extracellular-regulated protein kinases 1 (ERK1). Further, we confirmed that C10 can regulate the expressions of vascular endothelial growth factor 1 (VEGF-1), transforming growth factor-β2 (TGF-β2), intercellular cell adhesion molecule-1 (ICAM-1), p53, and matrix metalloproteinase 1 (MMP-1) genes associated with tumor apoptosis, migration, and invasion. Thus, C10 exhibits stronger anticancer activity with novel molecular targets and regulatory molecular mechanisms, indicating its great potency for development as a novel targeted anticancer drug.

show abstract

“…We applied the same statistical analysis methods as previously reported [21]. A student's test was used for data analysis.…”

Section: Discussionmentioning

confidence: 99%

“…All equipment and biological agents used in this study were as previously reported [18,21]. The other reagents were of analytical grade.…”

Section: Methodsmentioning

confidence: 99%

Section: Cell Apoptosis Assaymentioning

confidence: 99%

Section: Genes Expression Assaymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3’, 5’-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

A Dual‐Targeting Circular Aptamer Strategy Enables the Recognition of Different Leukemia Cells with Enhanced Binding Ability

Peng

et al. 2022

Angewandte Chemie

View full text Add to dashboard Cite

Currently, the broad use of monovalent aptamers in oncology faces challenges, including insufficient recognition and internalization caused by a finite number of receptors on the cell surface, as well as a confined recognition spectrum. Herein, we describe the development of a dual‐targeting circular aptamer (DTCA) that can recognize two different biomarkers on living cells to augment aptamer–receptor interactions, thus enhancing recognition of the target cells. This improvement not only boosts binding and internalization abilities, but also expands the recognition spectrum of these aptamers to different leukemia cells. Moreover, the stability of DTCA in serum can be significantly improved by an enzyme‐promoted terminal ligation strategy. The chemical incorporation of 5‐fluorodeoxyuridine into DTCA resulted in a pharmaceutically functional aptamer that exhibited excellent selectivity, as demonstrated by its high cytotoxicity against target cancer cells, but not to normal cells. The superiority of our newly developed strategy was further highlighted by its precise tumor‐imaging capability.

show abstract

A Dual‐Targeting Circular Aptamer Strategy Enables the Recognition of Different Leukemia Cells with Enhanced Binding Ability

Peng

et al. 2022

Angew Chem Int Ed

View full text Add to dashboard Cite

show abstract

A novel synthesized 3’, 5’-diprenylated chalcone mediates the proliferation of human leukemia cells by regulating apoptosis and autophagy pathways

Cited by 28 publications

References 37 publications

Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3’, 5’-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells

Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3’, 5’-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells

A Dual‐Targeting Circular Aptamer Strategy Enables the Recognition of Different Leukemia Cells with Enhanced Binding Ability

A Dual‐Targeting Circular Aptamer Strategy Enables the Recognition of Different Leukemia Cells with Enhanced Binding Ability

Contact Info

Product

Resources

About